Michael Havert, PhD | SVP Regulatory Affairs
Michael Havert joined Nanoscope Therapeutics in January 2023 as Senior Vice President, Regulatory Affairs. He brings nearly 20 years of experience across regulatory, quality and CMC aspects of cell and gene therapies both as a team member of several startups, and as a leader within the FDA. Previously, Michael has held senior executive positions in Regulatory Affairs at CBMG, StrideBio, and Bluebird Bio. Prior to that, Mike held positions of increasing responsibility within the FDA (CBER) including having served as BLA Review Chair, championing the release of guidance documents, and working toward global harmonization efforts. Michael holds a PhD from the University of Wisconsin, Madison, and conducted postdoctoral fellowships in virology at JHU and NIH.
